Evaluation of myeloid cells (tumor-associated tissue eosinophils and mast cells) infiltration in different grades of oral squamous cell carcinoma.
BACKGROUND
The multifunctional involvement and infiltration of myeloid cells (tumor-associated tissue eosinophils [TATE] and mast cells) can provide a unique opportunity to define relevant effectors functions that may represent novel, therapeutic options for modulation of tumor onset/growth.


OBJECTIVE
Our study aimed to evaluate infiltration of myeloid cells (TATE and Mast cells) infiltration in different grades (WHO grading) of oral squamous cell carcinoma (OSCC).


METHODS
Total 30 cases of OSCC were selected for this study. Hematoxylin and eosin stain and toluidine blue special stain, to evaluate TATE and the mast cells infiltration, were used. Three-year follow-up of OSCC cases was done.


RESULTS
Among 30 cases, 63.33% cases of OSCC showed TATE-positive and 36.66% cases showed TATE-negative. Regarding mast cells infiltration, 66.66% OSCC cases showed mast cells positive and 33.33% cases did not show significant mast cells infiltration. We found significant association of TATE and mast cells infiltration in OSCC cases. These myeloid cells infiltration significantly associated with age of patients but did not show any significant association with gender, site, and habit of cases. When we compared these cells infiltration with clinical stages and different histological grades of tumor, we found their infiltration is decreasing, from Stages 1 to Stage 3 of tumor and from well to poorly differentiated carcinoma. We have also found the less infiltration of these myeloid in recurrence cases of OSCC.


CONCLUSIONS
As the infiltration of TATE and mast cells are correlated, along with evaluation of TATE, we should also evaluate the presence of mast cells infiltration in OSCC. The assessment of myeloid cells could become, in the future, useful for therapeutic approaches in this subset of the patient.
Department of Oral and Maxillofacial Pathology, Institute of Dental Science, SOA University, Bhubaneswar, Odisha, India.
Priyanka
P
Debta
Department of Oral Medicine and Radiology, S.C.B. Dental College and Hospital, Cuttack, Odisha, India.
Fakir Mohan
FM
Debta
Department of Oral and Maxillofacial Pathology, SPDC, Sawangi, Wardha, Maharashtra, India.
Minal
M
Chaudhary
Department of Oral and Maxillofacial Pathology, Aditya Dental College, Beed, Maharashtra, India.
Smita
S
Bussari
Mast cells; oral squamous cell carcinoma; toluidine blue; tumor-associated tissue eosinophils
Cancer. 1988 Dec 1;62(11):2416-9
3179960
BMC Cancer. 2005 Sep 21;5:121
16176582
Clin Exp Allergy. 2008 May;38(5):709-50
18384431
J Surg Oncol. 1993 Jun;53(2):92-6
8501912
Nat Rev Immunol. 2008 Jun;8(6):478-86
18483499
Blood. 1981 Dec;58(6):1175-81
6272905
Immunology. 1996 Jan;87(1):149-54
8666427
Cancer Immunol Res. 2013 Nov;1(5):269-79
24777963
Ann Thorac Surg. 2000 Jun;69(6):1686-90
10892907
J Oral Pathol Med. 2003 Apr;32(4):195-9
12653857
Otolaryngol Head Neck Surg. 2005 Jun;132(6):869-73
15944557
Am J Surg. 1994 Nov;168(5):469-71
7977976
Cancer Lett. 2008 Sep 28;269(1):1-6
18450371
Cancer Lett. 2006 Oct 8;242(1):1-10
16413116
Am J Med Sci. 1993 Sep;306(3):185-91
8128982
Carcinogenesis. 2008 Apr;29(4):880-6
18258601
Histol Histopathol. 2003 Jul;18(3):709-13
12792882
Cancer Cell Int. 2006 Dec 19;6:28
17177999
Immunol Lett. 2011 Jul;138(1):28-31
21333679
Oral Oncol. 2006 Sep;42(8):849-50
16829160
Nat Immunol. 2005 Feb;6(2):135-42
15662442
J Cell Biol. 1966 Nov 1;31(2):349-62
19866705
J Inflamm (Lond). 2013 Jan 31;10(1):4
23369060
Otolaryngol Head Neck Surg. 1992 Jan;106(1):27-33
1734363
J Biol Chem. 1996 Nov 1;271(44):27500-8
8910334
Libyan J Med. 2007 Mar 01;2(1):30-9
21503229
Scand J Haematol. 1977 Aug;19(2):129-44
897557
J Natl Cancer Inst. 1982 Dec;69(6):1305-9
6982995
Histopathology. 1984 Jul;8(4):627-32
6479905
Trends Immunol. 2004 May;25(5):235-41
15099563
Histopathology. 2002 Aug;41(2):152-7
12147093
Anticancer Res. 2002 Sep-Oct;22(5):2623-7
12529973
Immunology. 1996 Jan;87(1):155-61
8666429
Hua Xi Kou Qiang Yi Xue Za Zhi. 1997 Aug;15(3):228-9, 232
11480005
Auris Nasus Larynx. 2002 Apr;29(2):175-81
11893453
Mol Ther. 2006 Jan;13(1):183-93
16125469
Cancer J. 2005 May-Jun;11(3):217-25
16053665
J Clin Immunol. 1998 May;18(3):169-83
9624576
Int Arch Allergy Immunol. 1999 Feb-Apr;118(2-4):426-8
10224465
Int J Cancer. 1993 Apr 22;54(1):8-15
8386711
J Clin Pathol. 1981 Dec;34(12):1343-8
7035499
Cancer Treat Res. 2005;123:89-111
16211867
J Immunol. 2001 Oct 1;167(7):4008-16
11564820
Nat Rev Immunol. 2004 Oct;4(10):787-99
15459670
Br J Obstet Gynaecol. 1988 Apr;95(4):393-401
3382614
J Leukoc Biol. 2006 Jun;79(6):1131-9
16617160
Immunity. 2012 Jul 27;37(1):13-24
22840840
Anticancer Res. 2000 Sep-Oct;20(5A):3025-30
11062718
Ann Diagn Pathol. 2008 Oct;12(5):322-7
18774493
Clin Cancer Res. 2005 Mar 1;11(5):1899-909
15756016
CA Cancer J Clin. 1994 Jan-Feb;44(1):7-26
8281473
Nat Rev Immunol. 2004 Dec;4(12):941-52
15573129
J Exp Med. 2001 Jul 2;194(1):F1-5
11435478
Curr Opin Hematol. 2000 Jan;7(1):32-9
10608502
Exp Dermatol. 2003 Dec;12(6):886-910
14719507
Open Dent J. 2008 Nov 28;2:126-32
19444318
J Allergy Clin Immunol. 1998 Sep;102(3):454-60
9768588
Immunol Invest. 2003 Feb;32(1-2):17-30
12722939
N Engl J Med. 2008 Jun 19;358(25):2704-15
18565863
Cancer Res. 1983 Jun;43(6):2997-3000
6850611
Otolaryngol Head Neck Surg. 1987 Apr;96(4):319-24
3108818
Nature. 2005 Dec 15;438(7070):967-74
16355214